'Activity dependent' diaporamas de présentation

Synaptogenesis

615 views • 40 slides

Synaptogenesis

419 views • 40 slides

Synaptic plasticity: Introduction

538 views • 37 slides

High/Correlated activity

Magic. Magic. LTP. LTD. High/Correlated activity. Low/uncorrelated activity. High NMDA-R activation. Moderate NMDA-R activation. High Calcium. Moderate Calcium. LTP. LTD. What changes during synaptic plasticity?

397 views • 32 slides

High/Correlated activity

Magic. Magic. LTP. LTD. High/Correlated activity. Low/uncorrelated activity. High NMDA-R activation. Moderate NMDA-R activation. High Calcium. Moderate Calcium. LTP. LTD. What changes during the expression of synaptic plasticity? Is expression pre or post-synaptic

398 views • 30 slides

Activity-Dependent Development II April 25, 2007 Mu-ming Poo

Activity-Dependent Development II April 25, 2007 Mu-ming Poo. The neurotrophin hypothesis Maps in somatic sensory and motor cortices Development of retinotopic map Reorganization of cortical maps following sensory deprivation Synaptic basis of cortical plasticity --- LTP and LTD

357 views • 19 slides

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions. Tom Sutula, MD, PhD Department of Neurology, University of Wisconsin Chief Scientific Officer, NeuroGenomex, Inc. The novel mechanism of 2DG: why 2DG is a glycolytic inhibitor.

451 views • 18 slides

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions. Tom Sutula, MD, PhD Department of Neurology, University of Wisconsin Chief Scientific Officer, NeuroGenomex, Inc. The novel mechanism of 2DG: why 2DG is a glycolytic inhibitor.

283 views • 18 slides

GW610

125 views • 1 slides